Biomedical Center of LFP UK

The team at the Laboratory of Pharmacogenomics of the Biomedical Center of LFP UK in Pilsen has published a new experimental article in the journal Molecular Oncology (Q1 in the field of Oncology). The study focuses on the role of the miR-195-5p/CHEK1 axis in the prognosis and treatment of luminal breast carcinomas. Through integrative miRNA profiling of more than 100 estrogen positive tumors, the authors identified miR-195-5p as a key negative regulator of the CHEK1 gene, which governs the cell cycle and DNA damage response. The results were supported by functional experiments in cell line models, where miR-195-5p significantly reduced the expression of CHEK1 and other genes associated with proliferation. While miR-195-5p transfection alone was not sufficient to enhance the effect of the chemotherapeutic agent doxorubicin, the combination of doxorubicin with the specific CHEK1 inhibitor rabusertib led to a significant increase in the cytotoxic effect. These findings support the potential use of CHEK1-targeted therapy to enhance the efficacy of standard chemotherapy in patients with highly proliferative luminal tumors. The study also highlights the potential of microRNAs as biomarkers and underscores new possibilities for combination therapy that may lead to a personalized approach in breast cancer treatment. Boušková et al.: Integrative miRNome profiling reveals the miR-195-5p—CHEK1 axis and its impact on luminal breast cancer outcomes. http://doi.org/10.1002/1878-0261.70077